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The New Genetics
ALTHOUGH THE COMPLETED PHASE of the Human
Genome Project has provided the entire human DNA
sequence, the next challenge is to determine the functions of
most of the ~35 000 genes in the human genome. Each day,
researchers discover the functions of new genes and increase
the knowledge that can be translated into clinical practice.
This growth in knowledge fuels, in turn, the expansion of
DNA testing both for diagnosis and for prediction of disease
susceptibility. Clinicians, whether in general practice or in
other specialties, need to accommodate the “new genetics”,
with its focus on DNA variation and its role in disease.
In the new genetics that has emerged from DNA-based
information, the doctor–patient relationship becomes more
complex, as knowledge of an individual’s DNA status has
health implications not only for the individual, but also for
the family. The management of a genetic disorder is likely to
involve family members, making follow-up and counselling
potentially more difficult logistically, and to evoke ethical
issues, such as the privacy of the individual versus the
potential benefits to family members. General practitioners
are at the “coalface” of the new genetics because of their
close links with the patient and involved families.
When a genetic condition can be detected but no treat-
ment is available, long term management and follow-up can
unleash a constellation of medical, psychosocial and repro-
ductive issues. This can be illustrated by apolipoprotein E
(APOE) genetic tests, which can predict elevated risks for
common conditions such as coronary artery disease or
Alzheimer’s disease.1 In this environment, the GP and other
specialists are all key players with their particular in-depth
knowledge of the medical issues.
The challenges for doctors will be finding the time and
commitment to deal with the inexorable changes in clinical
practice as the new genetics becomes increasingly involved
in all areas of medicine. Counselling and ethical issues
related to familial disease require new skills, and more
resources. Increasingly, GPs and specialists, including clini-
cal geneticists and genetic counsellors, will need to work as
part of a molecular medicine (DNA) team to provide the
necessary range of skills.
The impact of the new genetics on clinical practice is
highlighted in the Box, which details clinical decision path-
ways in four different management spheres of the new
genetics: diagnostic, prenatal, predictive/presymptomatic
and screening genetics. The potential directions in these
decision mazes are explored in the following scenarios.
Diagnostic DNA testing
In this scenario, a patient presents with clinical features of a
disorder, and a DNA test is undertaken to confirm a
diagnosis. For example, diabetes, altered skin pigmentation
and a persistently raised ferritin level would be consistent
with haemochromatosis. Confirmation would previously
have required liver biopsy, but an alternative, non-invasive
option with the new genetics is a DNA test.2 There is a
question of whether the GP should refer to a specialist, or
independently initiate the DNA test, which looks for the
common mutation C282Y (Box).2 Initiating the test is
reasonable if the GP understands the implications of the
DNA test result, including the significance of a negative
result. The GP also needs to understand the test’s depend-
ence on the ethnic background of the person being tested.
C282Y is predominantly found in people with a north-
western European background. Failure to find C282Y in an
individual of Asian or Mediterranean background is less
helpful, as the predominant mutation in these populations is
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H63D, and the significance of this mutation in terms of
developing clinical haemochromatosis remains unclear.2,3
The genetic laboratory can provide a result, but cannot be
expected to give a definitive interpretation of the result’s
significance without adequate clinical information as to why
the test was ordered.
Once the clinical diagnosis is confirmed, the patient can
be treated, but the management should also include family
members at risk, who will also need counselling. If agreea-
ble, at-risk family members might need DNA testing to
predict the future development of a genetic disorder. In
these circumstances a key question is who will be responsi-
ble for the family testing and counselling. Will it be the
specialist, the GP or the genetic counselling service now
available in most public hospitals in Australia and in out-
reach clinics in rural centres? We propose that a team
approach in diagnostic genetics will produce the best result
for the patient and family, as it will combine the clinical and
laboratory expertise (specialists), the genetics knowledge
(genetics clinic) and the long term care of the patient and
family (GP).
Prenatal DNA testing
Two possible prenatal testing scenarios exist. The first
involves a pregnancy that has high risk for a genetic disorder
or fetal abnormality. This risk is identified because of a
family history, as when one of the partners is a known
carrier of a disease such as cystic fibrosis, or because of
advanced maternal age, with its associated risk of a chromo-
somal disorder such as Down syndrome. People in these
situations are often best referred to a specialist genetics
clinic or fetal medicine unit, where the risk can be accurately
determined and the pregnancy managed accordingly (Box).
The second prenatal testing scenario is when couples
wishing to start a family make a general inquiry about risks,
or procedures available to monitor their pregnancy. This
scenario includes carrier testing for thalassaemia, maternal
serum screening using biochemical markers to identify
conditions such as Down syndrome or neural tube defects,
as well as first-trimester ultrasound studies for Down syn-
drome or structural abnormalities. Couples with no specific
risk factors but wanting information could be managed by
GPs or obstetricians who have the necessary knowledge and
counselling skills.
Predictive or presymptomatic DNA testing
Predictive or presymptomatic DNA testing allows genetic
disorders to be detected in advance of clinical presentation.
This ability to predict disease development before symp-
toms or signs occur is a particularly powerful new option.
For example, offspring of a parent with familial adenoma-
tous polyposis (FAP) have a 50% chance of inheriting the
abnormal gene. Once the parental FAP DNA mutation is
known, the offspring can have a DNA test to determine if
they have inherited the normal parental gene (ie, they are no
longer at risk) or the gene with the DNA mutation (ie, they
Decision pathways in four scenarios involving the “new genetics”
The flow chart, drawn in the form of a pedigree, illustrates key players in the “new genetics” (patient, family, GP/specialist, other health 
professionals, genetic support groups, the community). The consultation usually starts with a patient or family problem, and ends, in the more 
complex genetic disorders, with input being required from other health professionals and genetic support groups. The optimal provision of the 
various alternatives in the new genetics (diagnostic, prenatal, predictive and screening DNA testing) remains a challenge for the future.
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will definitely develop FAP at some future date). In the
latter case, the onset of the disease can be predicted long
before there are any clinical features, and with it the
associated risk for colon cancer. On the other hand, predic-
tive genetics can lead to adverse psychosocial consequences
if the individual or the family cannot cope with this predic-
tive information. Furthermore, there is the possibility of
discrimination, as the individual is labelled with a disease
that has yet to develop, or indeed might never develop. High
profile examples of predictive testing include BRCA1 and
BRCA2 genes for breast cancer, and genes for a number of
serious and non-treatable adult-onset neurological disor-
ders, such as Huntington disease.4,5 The haemochromatosis
scenario also involves predictive genetics, but is less emotive,
as there is a relatively simple intervention (regular venesec-
tion) to prevent or treat this condition.
Because patients undergoing predictive DNA testing have
no symptoms or clinical signs, it is particularly important
that this type of DNA testing is undertaken appropriately,
that counselling implications are addressed before testing,
and that support services are available afterwards.6 Getting
the answer wrong either way has long-term implications
which could lead to inappropriate lifestyle decisions for the
patient and family, and distress when the truth belatedly
becomes known. Because of the complexities associated
with predictive testing, the requirement for experienced and
intensive counselling and the necessity, in some cases, for
ongoing support, it is essential that tests predictive of serious
diseases (such as breast cancer or Huntington disease) be
initiated through a clinical genetics service that has appro-
priate skills and resources. The Box recommends referral for
all predictive DNA tests, although there will be exceptions.
Examples of tests that might not require referral are haemo-
chromatosis or predisposition to thrombosis through the
Factor V Leiden DNA mutation.2,7 A medical practitioner
who deals with the clinical consequences of these disorders
should be well placed to interpret the DNA test result
(taking into consideration interacting environmental and
other genetic factors), and be able to explain that not all
people testing positive will develop the disorder, particularly
if appropriate interventions are followed. The caveat to this
is that the medical practitioner is sufficiently trained in both
basic knowledge and counselling skills required for this level
of predictive genetic testing.
Screening DNA testing
In this scenario, there are two broad screening strategies:
family and community.
An example of family screening is DNA testing for
cystic fibrosis carrier status. The carriers are completely
healthy, and the implications of a positive test result are
relevant only for decisions involving reproduction. Testing
might be offered to close relatives at high risk, or to the
wider family.
Community screening has many variations. For exam-
ple, screening can be based on increased predisposition
because of ethnic background (as for thalassaemia in people
of Mediterranean, Middle Eastern or Asian origin, or Tay–
Sachs disease for Ashkenazi Jews). In other cases, commu-
nity screening could identify people with a gene mutation to
establish a population-based prevention program. An exam-
ple would be testing for haemochromatosis in the general
population with a view to preventing the disease by prophy-
lactic venesection.8 A third example of community screen-
ing is the newborn screening program, which tests for
common or preventable diseases that require early treat-
ment, such as phenylketonuria (PKU) and hypothyroidism.
Family screening can be arranged through GPs or special-
ists, depending on their knowledge and the complexity of
the underlying disorder (Box). On the other hand, the value
of community screening varies from case to case, and
consent is a more complex issue. For example, PKU
screening is universal in developed countries and has saved
countless individuals from intellectual handicap, whereas
community screening for haemochromatosis is still contro-
versial.2,3 Many individuals and families, prompted by
media stories, will approach their GP to inquire about
genetic testing, making the healthcare professional an
important “gatekeeper” for genetic knowledge. The GP will
have appropriate resources to answer some questions, but in
other cases should refer to the specialist or make use of other
healthcare professionals and genetic support groups.
Challenges ahead
The new DNA-based genetics will have an increasing
impact on medical practice. Few doctors currently under-
stand the complexities involved in counselling and in inter-
preting DNA tests, or the rapidly moving field of genetics
that is technology-driven and relies on computer-based
knowledge. This might lead to a suggestion that the new
genetics can only be adequately handled by experts within a
clinical genetics unit where there will be the skills to ensure
that patients (and their families) undergo appropriate DNA
testing, with the best outcomes. However, this option has
drawbacks. Many diseases with a genetic component to
aetiology, such as cancer, heart disease and haemochroma-
tosis, are very common, and resources in clinical genetics
units are limited. Most importantly, long term medical
management and support of the patient and family may well
be compromised if the GP and specialist are not directly
involved in offering care based on this new and powerful
means of diagnosis.
It is unrealistic to expect every doctor to have the
knowledge, time or resources to deal with all aspects of the
new genetics. This is an opportunity for the colleges or
universities to devise programs that allow interested doctors
to seek additional training. This skill would need to be
recognised, including a financial incentive to ensure that
the time commitment required for genetic counselling and
family follow-up is available. In this way, a cohort of GPs
and specialists can take their place in the molecular medi-
cine (DNA) team rather than simply functioning as a
source of referral. In 1999, new Medical Benefits Schedule
items were introduced to enhance GPs’ ability to coordi-
nate more complex care of patients such as might occur
with genetic counselling. However, this has not proven to
MJA Vol 178 21 April 2003 409
THE NEW GENETICS
be very successful,9 and more innovative ways need to be
considered.
In this brief overview of the new genetics, we have focused
on DNA technology and its impact on clinical practice. The
overview was given to several healthcare professionals who
were invited to provide more substantial articles on the
various issues related to the new genetics. We hope that the
articles in this series will prove informative, and a focus for
debate. This is a timely series, as, in 2003, the joint
Australian Law Reform Commission/National Health and
Medical Research Council Australian Health Ethics Com-
mittee Enquiry into the Protection of Human Genetic
Information will deliver to the federal Attorney General and
the federal Minister for Health recommendations that will
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